By FRANK LEAHY This is the second of two pieces. The first told the story of “Rick,” a 77-year-old Humana Medicare Advantage member who nearly lost his sight in a months-long runaround over a retinal detachment. This one asks what his case reveals, and what would help fix it. The runaround was exhausting – the…
The House VA Committee voted 19-0 to subpoena Oracle Health executives Larry Ellison and Mike Sicilia after learning the VA’s EHR contract ballooned from $10 billion to $27 billion — despite Oracle’s promise to Congress that it would absorb any costs beyond the original cap. The post Oracle Health Execs Subpoenaed After VA Contract Costs…
Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the market without a commercialization partner. The post FDA Approves Ionis Pharma Drug, the First for…
Three things ski patrol can teach about building a business The post Bringing Ski Patrol Lessons to Healthtech Entrepreneurship appeared first on MedCity News.
Judi Health expanded its healthcare network to offer specialized virtual care for cancer, autoimmune and GI conditions while helping employers reduce overall healthcare costs. The post Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem appeared first on MedCity News.
A roundup of the seven most notable hospital mergers and acquisitions announced or completed this summer, including Prisma Health’s acquisition of Erlanger Health and Sanford Health’s purchase of North Memorial Health The post 7 Hospital Mergers from Summer 2026 appeared first on MedCity News.
Five years of reimbursement certainty gives health systems a clearer path to build Hospital at Home, but workforce, technology and implementation challenges remain.
Embí will oversee the world’s largest biomedical library and shepherd the investment of its approximately $495 million annual budget.
Ultragenyx Pharmaceuticals’ apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The disappointing result has some readthrough to Ionis Pharmaceuticals and Oak Hill Bio, each in clinical development with Angelman drugs designed to work in a similar way as Ultragenyx’s failed…
States seek to expand EMS programs that do at-home visits that can help prevent readmissions through disease-specific assessments, chronic disease management, patient education, and medication reconciliation